Table 4: Safety outcomes of NSAIDs included in this study.

DrugNumber of trials includedTotal number of patients includedNumber of eventsRange of hepatotoxic eventsRange of proportion
(×10−2)
AST > 3 ULNALT > 3 ULNALT, AST, or both > 3 ULNALP > 2 ULNHy’s LawLiver-related discontinuationLiver-related hospitalization

Celecoxib4789211-20.13–0.38
Diclofenac111999839586419349243–8640.015–4.3
Etoricoxib11741216201571–1620.005–0.930

Remark. Hy’s Law: ALT > 3 ULN, and bilirubin ≥ 2 ULN; calculated from the minimal event and the maximal event due to the possibility of overlapping of patients.